Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurooncol ; 163(1): 185-194, 2023 May.
Article in English | MEDLINE | ID: mdl-37162667

ABSTRACT

PURPOSE: In addition to neurological symptoms glioblastoma (GBM) patients can experience psychiatric complaints, which are often hard to recognize and difficult to treat. Research on psychiatric symptoms during glioblastoma treatment is limited, but can have significant impact on quality of life, treatment processes and even survival. The aim of this study is to explore the incidence of clinically relevant psychiatric symptoms, during glioblastoma treatment and active surveillance. METHODS: Medical records of 302 GBM patients were reviewed from diagnostic surgery until discontinuation of treatment or active surveillance. Clinical relevance was defined as psychiatric symptoms that interfered with the oncological treatment and required referral to a psychiatrist. "Referred" versus "non-referred" GBM patients were compared using the Pearson Chi-Square test, Fisher's Exact Test or Mann Whitney-U test. RESULTS: Psychiatric symptoms occurred in 11.5% of patients during glioblastoma treatment or active surveillance, most often mood or behavioral symptoms, followed by psychotic symptoms. Referral occurred mainly during concomitant chemoradiation or adjuvant chemotherapy (64.3%). In 28.6% of patients psychiatric symptoms were thought to be attributive to medication. Treatment was discontinued in 17.9% of patients and temporarily interrupted in 3.6%. Possible risk factors included male gender, history of psychiatric disorder, postoperative delirium, non-frontal tumor location, anti-epileptic drug use at baseline and corticosteroid initiation during treatment. CONCLUSION: The found incidence of 11.5% and the high number of patients discontinuing treatment due to psychiatric symptoms justify more research in this, to date, understudied topic in scientific literature. Further prospective studies are needed to identify risk factors and unravel possible effects on survival.


Subject(s)
Brain Neoplasms , Glioblastoma , Mental Disorders , Humans , Male , Glioblastoma/therapy , Glioblastoma/drug therapy , Temozolomide/therapeutic use , Quality of Life , Incidence , Retrospective Studies , Mental Disorders/epidemiology , Mental Disorders/therapy , Brain Neoplasms/therapy , Brain Neoplasms/drug therapy
3.
Acta Orthop Belg ; 84(4): 452-460, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30879450

ABSTRACT

Optimal tibial component fixation in total knee arthroplasty (TKA) requires maximal tibial bone coverage, optimized mediolateral cortical fit as well as component rotation. Failure to achieve an optimal fit may result in component subsidence and loosening in case of undersizing, or overhang with subsequent soft tissue impingement in case of overhang. To date there is no consensus on optimal tibial component shape, and significant variability exists among different design manufacturers. In this study "principal component analysis" was used as a statistical tool in order to determine the ideal tibia baseplate shape, based upon anthropometric CT- scan data defining an average proximal tibial shape and variations. Gender specificity was evaluated and differences in geometry depending on anatomic constitution (varus, neutral, valgus) were analyzed. The results from our study indicate that in the arthritic knee differences in proximal tibial morphology at the resection level were mainly attributed to size and not shape. This is true for both Caucasian men and women, and is independent from the anatomical constitution.


Subject(s)
Arthroplasty, Replacement, Knee , Knee Prosthesis , Prosthesis Design , Tibia/surgery , Aged , Female , Humans , Male , Middle Aged , Principal Component Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...